-
Posted by
Two Blokes May 27, 2025 -
Filed in
Stock
-
4 views
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA\u00ae (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with recurrent, not amenable to curative surger.
